No abstract available.
Defibrillators ; Defibrillators, Implantable* ; Jugular Veins*

Electric accidents that are increasing can damage myocardium, lead to reduce contraction of myocardium, ventricular fibrillation, non-systole, and eventually cardiac arrest. Study on 35 patients with cardiac and breathing arrest since 1995-1997 shown that the youngest people were died when they contacted with low voltage due to arrhythmia. The first aid is very important, artificial respiration, cardiac massage, it shouldn't transfer to hospital when they have cardiac and breathing arrest. First dose of electric shock: 200J, second time: 3000J, and from third time: 4000J. It should use electric safe devices.
Defibrillators ; Cardiovascular Diseases

Using beta-blocker propranolone immediately after electric shock helped successful treatment in 2 female patients, 21 years old and 27 years old, who experienced schizophrenia (F20) and had treated by antidepressant drugs. After treatment, both of them were stable and only used drugs at median dose. After electric shock they ate and slept well, had stable behaviour, and pulse was 80-90 c/m. Patients discharged after 1 week
Depression ; Defibrillators ; Pharmaceutical Preparations

Defibrillators ; Humans ; Myocardial Infarction

Defibrillators, Implantable ; Electric Countershock

This paper introduces a new method which controls discharge energy accurately. It is achieved by calculating target voltage based on transthoracic impedance and accurately controlling charging voltage and discharge pulse width. A new defibrillator is designed and programmed using this method. The test results show that this method is valid and applicable to all kinds of external defibrillators.
Defibrillators ; standards ; Equipment Design

Cardiac rhythm management device (CRMD) infection is rare, but potentially life-threatening complication. Despite technical evolution of cardiac device, the cases of CRMD infection have increased remarkably over the past decades. In this review, several important key points were discussed with regards to the epidemiology, pathogenesis, risk factors, microbiology, clinical manifestations, diagnosis, treatment and prevention of CRMD infection.
Defibrillators ; Endocarditis ; Risk Factors

BACKGROUND: Radiofrequency ablation (RFA) is the recommended treatment of choice for supraventricular tachycardia (SVT), whereas implantable cardioverter-defibrillator (ICD) is recommended for patients at high risk for sudden death due to ventricular tachycardia/fibrillation. Radiofrequency ablation has been proven to improve the quality of life of patients with SVT, whereas an ICD has been shown to reduce mortality among patients at risk for sudden cardiac death. Both procedures are expensive and usually beyond the reach of the average Filipino patient. OBJECTIVES: The objectives are to (1) determine the cost of hospitalization for cardiac arrhythmias that require RFA and cardioverter-defibrillator implantation in the Philippines, (2) propose revised Philippine Health Insurance Corporation (PhilHealth) benefit packages for both procedures, and (3) determine the budget impact of the proposed revised packages. METHODS: Hospitalization costs were obtained for both RFA and cardioverter-defibrillator implantation from two government tertiary care hospitals. A range of hospitalization costs involving possible lower and higher cost scenarios was estimated. Based on these estimates and the yearly number of arrhythmias that require these procedures, revised benefit packages for both RFA and cardioverter-defibrillator implantation were proposed to PhilHealth. The budget impact analysis for the first 3 and 5 years of implementation of these revised packages was subsequently calculated. RESULTS: The estimated hospitalization costs for RFA ranged from Philippine pesos (PHP) 248,485 to 310,480, whereas for cardioverter-defibrillator implantation, the costs ranged from PHP 509,122 to 581,940. These amounts are greatly disparate from the present PhilHealth coverages, which are PHP 9700 and 18,000 for RFA and cardioverter-defibrillator implantation, respectively. Based on these hospitalization costs, the proposed RFA benefit package is PHP 275,000 to 310,000, whereas for an ICD benefit package, PHP 513,000 to 576,000 is proposed. The incremental cost of more than PHP 300 million for RFA and more than PHP 700 million for an ICD is distributed for the next 3 or 5 years of implementation for these benefit packages, respectively. CONCLUSION The present PhilHealth case rates for both RFA and cardioverter-defibrillator implantation are greatly underestimated, which probably is the reason for their underutilization. There is a need to revise these case rates with due consideration of their actual hospitalization costs to lessen inequity in accessing these procedures.
Radiofrequency Ablation ; Defibrillators, Implantable

No abstract available.
Defibrillators* ; Heart Failure, Systolic* ; Humans

No abstract available.
Defibrillators, Implantable* ; Humans ; Magnetic Resonance Imaging*